Effect of PCSK9 Inhibitor on Blood Lipid Levels in Patients with High and Very-High CVD Risk: A Systematic Review and Meta-Analysis

Effect of PCSK9 Inhibitor on Blood Lipid Levels in Patients with High and Very-High CVD Risk: A Systematic Review and Meta-Analysis

Objectives. We aimed to investigate the effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor on blood lipid levels in patients with high and very-high cardiovascular risk. Design. 14 trials (n = 52,586 patients) comparing treatment with or without PCSK9 inhibitors were retrieve...

Full description

Saved in:
Bibliographic Details
Main Authors: Yue Zhang, Yanrong Suo, Lin Yang, Xiaolu Zhang, Qun Yu, Miao Zeng, Wenlan Zhang, Xijuan Jiang, Yijing Wang
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Cardiology Research and Practice
Online Access:http://dx.doi.org/10.1155/2022/8729003
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items